NOTE
🌱 created from: myelofibrosis
Treatment of myelofibrosis
READ:
How I treat transplant-eligible patients with myelofibrosis
Kröger N, Wolschke C, Gagelmann N. How I treat transplant-eligible patients with myelofibrosis. Blood. 2023;142(20):1683-1696. doi:10.1182/blood.2023021218
The management of myelofibrosis: A British Society for Haematology Guideline
McLornan DP, Psaila B, Ewing J, et al. The management of myelofibrosis: A British Society for Haematology Guideline. British Journal of Haematology. 204(1):136-150. doi:10.1111/bjh.19186
JAK inhibitors
-
- How to adjust dose for ruxolitinib
- Monitor for skin cancer, TB, herpes
-
Transplant? MTSS when Ruxolitinib got the best response in the first place, around 3 months after the start of treatment
-
RR6 for response to ruxolitinib
-
second line:
- Momentum Simplify-1, Simplify-2
- PERSIS-2 for thrombocytopenia
Novel BET Inhibitor for Advanced Myelofibrosis INDEPENDENCE IMBark
TLDR
- High risk patients, consider HSCT in the first place or clinical trials
- low risk patients, consider Ruxolitinib,
- handle anemia, thrombocytopenia
- failure, then consider 2nd line JAKi